RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

Leukemia. 2014 Apr;28(4):977-9. doi: 10.1038/leu.2013.324. Epub 2013 Nov 4.

Authors

H Lilljebjörn¹, H Ågerstam¹, C Orsmark-Pietras¹, M Rissler¹, H Ehrencrona¹, L Nilsson², J Richter³, T Fioretos¹

Affiliations

¹ Department of Clinical Genetics, University and Regional Laboratories, Lund University, Lund, Sweden.
² Department of Hematology and Coagulation, Skåne University Hospital, Lund, Sweden.
³ 1] Department of Hematology and Coagulation, Skåne University Hospital, Lund, Sweden [2] Department of Molecular Medicine and Gene Therapy, Lund University, Lund, Sweden.

PMID: 24186003
DOI: 10.1038/leu.2013.324

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides / therapeutic use*
Gene Fusion*
Humans
Imatinib Mesylate
Leukemia / drug therapy
Leukemia / genetics*
MEF2 Transcription Factors / genetics
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Receptor, Macrophage Colony-Stimulating Factor / genetics*
Receptor, Platelet-Derived Growth Factor beta / genetics
Sequence Analysis, RNA*

Substances

Antineoplastic Agents
Benzamides
MEF2 Transcription Factors
MEF2D protein, human
Piperazines
Pyrimidines
Imatinib Mesylate
Receptor, Macrophage Colony-Stimulating Factor
Receptor, Platelet-Derived Growth Factor beta